Alnylam Pharmaceuticals (ALNY) Q1 2026 Earnings
Alnylam Pharmaceuticals reported Q1 2026 revenue of $1.2B (+96.4% YoY), beat analyst consensus of $1.1B by $51.7M. Diluted EPS came in at $1.51, beat the $0.87 consensus by $0.64. Alnylam Pharmaceuticals reports across 2 business segments, led by Commercial Medicines and Research and Development.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Alnylam Pharmaceuticals's Q1 2026 earnings report.
Alnylam Pharmaceuticals (ALNY) reported Q1 2026 earnings on April 30, 2026 before market open.
Alnylam Pharmaceuticals reported revenue of $1.2B and diluted EPS of $1.51 for Q1 2026.
Revenue beat the consensus estimate of $1.1B by $51.7M. EPS beat the consensus estimate of $0.87 by $0.64.
Compared to the same quarter a year prior, revenue grew 96.4% from $594.2M a year earlier.
You can read the 8-K earnings release (0001628280-26-028601) and the 10-Q periodic report (0001628280-26-028605) directly on SEC EDGAR. The filing index links above go to sec.gov.